Search
Choline
go.drugbank.com/drugs/DB00122ApprovedInvestigationalNutraceuticalA basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.
Mixtures: For-2, Multi-force for Women TabAbametapir
go.drugbank.com/drugs/DB11932ApprovedThe necessity for follow-up treatment may lead to challenges with patient adherence, and resistance to agents like permethrin and [pyrethrins]/[piperonyl butoxide] may be significant in some areas. … [A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163]
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigationalMetastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. … A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated approval for
Deflazacort
go.drugbank.com/drugs/DB11921Approved[L6694] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function.
Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, PlainNintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigational[L8453,L8459] It was first approved for use in the United States in 2014. … [A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459]
Padeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigationalPadeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies. … [A244559] Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a focal treatment for localized prostate cancer.
Categories: Heterocyclic Compounds with 4 or More RingsStannous chloride
go.drugbank.com/drugs/DB11056ApprovedThese complexes localize primarily in bone (40-50%) and infracted myocardium (0.01-0.02%/g of tissue) allowing for imaging of areas of altered osteogenesis or necrotic heart tissue [FDA Label]. … Tin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities [A32700].
Cemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigational[L43867] The EMA then approved Libtayo (cemiplimab) for that indication later in the same year. [L43872] … [L43872] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended cemiplimab be granted marketing authorization for the treatment of cervical cancer.
Alatrofloxacin
go.drugbank.com/drugs/DB09335ApprovedWithdrawnAlatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalOzanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. … [L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.